The objective of this study was to describe the epidemiology, clinical presentation and consequences of @entity2794 ( @entity2794 ) in France. A representative nation-wide sample of the general population was identified using a stratified sampling method. Ten thousand five hundred and eight-five subjects were screened in face-to-face interviews, and data collected using a standard questionnaire. An overall point prevalence of @entity2794 in the general population of 2.98% was observed. Two-thirds of these subjects presented @entity2704 -like features. Severity, functional impact and healthcare consumption were higher than in subjects reporting episodic @entity2704 in the same sample. Of the subjects, 28.2% reported the most severe @entity2704 disability assessment scores (Grades 3 and 4), compared to 12% of episodic migraineurs. A qualit   de vie et @entity2704 score of 68.4 was observed, indicating severely attenuated quality of life. Only 6.6% of subjects were taking prophylactic treatment, whilst 88% were using non-specific acute @entity10 treatments. The frequency of physician consultations and laboratory examinations was significantly higher than in individuals with @entity10 . @entity2794 is thus a relatively prevalent condition in the general French population, associated with an important burden of suffering and with considerable expenditure in the health service. Management of this condition is generally inappropriate.

Prevalence and description of XXXX in the general population in France.

@entity2704 :: ('MESH:D008881', 'Disease') :: ['migraine'] @entity10 :: ('MESH:D006261', 'Disease') :: ['episodic headache', 'headache'] @entity2794 :: ('MESH:D020773', 'Disease') :: ['CDH', 'chronic daily headache']
@entity2794 :: (MESH:D020773,Disease) :: ['chronic daily headache']
